Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

NCT06846606 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Acute Myeloid Leukemia (AML)
Refractory Acute Myeloid Leukemia (AML)
Relapsed/Refractory AML
Relapsed Myelodysplastic Syndromes
Refractory Myelodysplastic Syndromes
Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Interventions

DRUG: AUTX-703

Sponsor

Auron Therapeutics, Inc.